BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Peyronnet B, Mironska E, Chapple C, Cardozo L, Oelke M, Dmochowski R, Amarenco G, Gamé X, Kirby R, Van Der Aa F, Cornu JN. A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment. Eur Urol 2019;75:988-1000. [PMID: 30922690 DOI: 10.1016/j.eururo.2019.02.038] [Cited by in Crossref: 72] [Cited by in F6Publishing: 48] [Article Influence: 36.0] [Reference Citation Analysis]
Number Citing Articles
1 Riccetto CLZ. Editorial Comment: Combination therapy in overacti-ve bladder-untapped research opportunities: A systematic review of the literature. Int Braz J Urol 2021;47:661-2. [PMID: 33621018 DOI: 10.1590/S1677-5538.IBJU.2021.03.05] [Reference Citation Analysis]
2 Shkarupa D, Zaytseva A, Kubin N, Kovalev G, Shapovalova E. Native tissue repair of cardinal/uterosacral ligaments cures overactive bladder and prolapse, but only in pre-menopausal women. Cent European J Urol 2021;74:372-8. [PMID: 34729228 DOI: 10.5173/ceju.2021.285.3] [Reference Citation Analysis]
3 Lee WC, Leu S, Wu KLH, Tain YL, Chuang YC, Chan JYH. Tadalafil ameliorates bladder overactivity by restoring insulin-activated detrusor relaxation via the bladder mucosal IRS/PI3K/AKT/eNOS pathway in fructose-fed rats. Sci Rep 2021;11:8202. [PMID: 33859259 DOI: 10.1038/s41598-021-87505-3] [Reference Citation Analysis]
4 Lamerton TJ, Mielke GI, Brown WJ. Urinary incontinence in young women: Risk factors, management strategies, help-seeking behavior, and perceptions about bladder control. Neurourol Urodyn 2020;39:2284-92. [PMID: 32805080 DOI: 10.1002/nau.24483] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Mizutani H, Sakakibara F, Sasaki E. TAS-303 Ameliorates Carbachol-Induced Detrusor Overactivity in Rats, Revealing Its Therapeutic Potential for Overactive Bladder. J Pharmacol Exp Ther 2020;374:84-92. [PMID: 32332112 DOI: 10.1124/jpet.119.264572] [Reference Citation Analysis]
6 Malde S, Apostilidis A, Selai C, Rahnama'i MS, Marcelissen T, Cardozo L, Lovick T. Botulinum toxin A for refractory OAB and idiopathic urinary retention: Can phenotyping improve outcome for patients: ICI-RS 2019? Neurourol Urodyn 2020;39 Suppl 3:S104-12. [PMID: 31692092 DOI: 10.1002/nau.24207] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Brière R, Versi E, Richard PO, Gratton M, Tu LM. AUTHOR REPLY. Urology 2020;136:94. [PMID: 32033687 DOI: 10.1016/j.urology.2019.08.065] [Reference Citation Analysis]
8 Shoemaker R, Kim J. Urobiome: An outlook on the metagenome of urological diseases. Investig Clin Urol 2021;62:611-22. [PMID: 34729961 DOI: 10.4111/icu.20210312] [Reference Citation Analysis]
9 Yang E, Hu SW, Chen SL, Chen GD, Ng SC. A 3-year longitudinal survey of overactive bladder in community-dwelling male residents aged 40 years and above. Low Urin Tract Symptoms 2021;13:356-60. [PMID: 33594797 DOI: 10.1111/luts.12375] [Reference Citation Analysis]
10 Selvi I. Comment on "A multicenter prospective study for overactive bladder patient treatment satisfaction with mirabegron after being unsatisfied with antimuscarinic therapy (FAVOR study)". Neurourol Urodyn 2021;40:735-6. [PMID: 33508150 DOI: 10.1002/nau.24611] [Reference Citation Analysis]
11 Antunes-Lopes T, Cruz F. Urinary Biomarkers in Overactive Bladder: Revisiting the Evidence in 2019. Eur Urol Focus 2019;5:329-36. [PMID: 31231010 DOI: 10.1016/j.euf.2019.06.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
12 Ghijselings L, Hervé F, Van der Aa F, De Wachter S, Pauwaert K, Haddad R, Beeckman D, Pattyn P, Everaert K. Development of a flowchart reflecting the current attitude and approach towards idiopathic overactive bladder treatment in Belgium: A Delphi study. Neurourol Urodyn 2020;39:1781-95. [PMID: 32531082 DOI: 10.1002/nau.24421] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Wu YH, Chueh KS, Chuang SM, Long CY, Lu JH, Juan YS. Bladder Hyperactivity Induced by Oxidative Stress and Bladder Ischemia: A Review of Treatment Strategies with Antioxidants. Int J Mol Sci 2021;22:6014. [PMID: 34199527 DOI: 10.3390/ijms22116014] [Reference Citation Analysis]
14 Brière R, Versi E, Richard PO, Gratton M, Tu LM. A Preliminary Study on the Impact of Detrusor Overactivity on the Efficacy of Selective Bladder Denervation for the Treatment of Female Refractory Overactive Bladder. Urology 2020;136:88-94. [PMID: 31794815 DOI: 10.1016/j.urology.2019.08.061] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Firouzmand S, Young JS. A pilot study to investigate the associations of urinary concentrations of NO, ATP and derivatives with overactive bladder symptom severity. Exp Physiol 2020;105:932-9. [PMID: 32170890 DOI: 10.1113/EP088450] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Molnár PJ, Dér B, Borsodi K, Balla H, Borbás Z, Molnár K, Ruisanchez É, Kenessey I, Horváth A, Keszthelyi A, Majoros A, Nyirády P, Offermanns S, Benyó Z. Isoprostanes evoke contraction of the murine and human detrusor muscle via activation of the thromboxane prostanoid TP receptor and Rho kinase. Am J Physiol Renal Physiol 2021;320:F537-47. [PMID: 33491563 DOI: 10.1152/ajprenal.00400.2020] [Reference Citation Analysis]
17 Zhou J, Jiang C, Wang P, He S, Qi Z, Shao S, Tang Y. Effects and safety of herbal medicines on patients with overactive bladder: A protocol for a systematic view and meta-analysis. Medicine (Baltimore) 2019;98:e17005. [PMID: 31517818 DOI: 10.1097/MD.0000000000017005] [Reference Citation Analysis]
18 Lee D, Koo KC, Yoo JW, Lee KS. Effect of systemic atherosclerosis on overactive bladder symptoms in men with benign prostatic hyperplasia. Low Urin Tract Symptoms 2021. [PMID: 34323012 DOI: 10.1111/luts.12406] [Reference Citation Analysis]
19 Tay LJ, Harry D, Malde S, Sahai A. Cost Effectiveness of Sacral Neuromodulation and OnabotulinumtoxinA in Managing Refractory Idiopathic Overactive Bladder. Urology 2021;149:1-10. [PMID: 33227305 DOI: 10.1016/j.urology.2020.11.018] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Welk B, Richardson K, Panicker JN. The cognitive effect of anticholinergics for patients with overactive bladder. Nat Rev Urol 2021;18:686-700. [PMID: 34429535 DOI: 10.1038/s41585-021-00504-x] [Reference Citation Analysis]
21 Schimit GTF, Gregorio EP, Averbeck MA, de Souza MJ, da Silva ACM, Tavares DR, de Almeida SHM. Is There a Link Between Carotid Atherosclerosis and Idiopathic Overactive Bladder Among Women with Metabolic Syndrome? Res Rep Urol 2020;12:43-8. [PMID: 32110552 DOI: 10.2147/RRU.S244758] [Reference Citation Analysis]
22 Andersson K. Agents in early development for treatment of bladder dysfunction – promise of drugs acting at TRP channels? Expert Opinion on Investigational Drugs 2019;28:749-55. [DOI: 10.1080/13543784.2019.1654994] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
23 Rechberger E, Skorupska K, Rechberger T, Wojtaś M, Miotła P, Kulik-Rechberger B, Wróbel A. The Influence of Vaginal Native Tissues Pelvic Floor Reconstructive Surgery in Patients with Symptomatic Pelvic Organ Prolapse on Preexisting Storage Lower Urinary Tract Symptoms (LUTS). J Clin Med 2020;9:E829. [PMID: 32197495 DOI: 10.3390/jcm9030829] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
24 De Nunzio C, Brucker B, Bschleipfer T, Cornu JN, Drake MJ, Fusco F, Gravas S, Oelke M, Peyronnet B, Tutolo M, van Koeveringe G, Madersbacher S. Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men. Eur Urol 2021;79:492-504. [PMID: 33402296 DOI: 10.1016/j.eururo.2020.12.032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
25 Shin JH, Ryu CM, Yu HY, Shin DM, Choo MS. Current and Future Directions of Stem Cell Therapy for Bladder Dysfunction. Stem Cell Rev Rep 2020;16:82-93. [PMID: 31758372 DOI: 10.1007/s12015-019-09922-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
26 Bentellis I, Guérin S, Khene ZE, Khavari R, Peyronnet B. Artificial intelligence in functional urology: how it may shape the future. Curr Opin Urol 2021;31:385-90. [PMID: 33989231 DOI: 10.1097/MOU.0000000000000888] [Reference Citation Analysis]
27 Elbaset MA, Taha D, Sharaf DE, Ashour R, El-hefnawy AS. Obesity and Overactive Bladder: Is It a Matter of Body Weight, Fat Distribution or Function? A Preliminary Results. Urology 2020;143:91-6. [DOI: 10.1016/j.urology.2020.04.115] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
28 Kinno K, Sekido N, Takeuchi Y, Sawada Y, Watanabe S, Yoshimura Y. Association between overactive bladder and pelvic organ mobility as evaluated by dynamic magnetic resonance imaging. Sci Rep 2021;11:13726. [PMID: 34215810 DOI: 10.1038/s41598-021-93143-6] [Reference Citation Analysis]
29 Fry CH, Chakrabarty B, Hashitani H, Andersson KE, McCloskey K, Jabr RI, Drake MJ. New targets for overactive bladder-ICI-RS 2109. Neurourol Urodyn 2020;39 Suppl 3:S113-21. [PMID: 31737931 DOI: 10.1002/nau.24228] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
30 Hartigan SM, Dmochowski RR. Gender specific pharmacokinetic and pharmacodynamic considerations for antimuscarinic drugs for overactive bladder treatment. Expert Opin Drug Metab Toxicol 2020;16:103-10. [PMID: 31918590 DOI: 10.1080/17425255.2020.1714591] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
31 Çırakoğlu A, Fejzullahu A, Benli E, Yuce A, Ayyıldız A, Aynacıoğlu AŞ. Association between the Trp64Arg polymorphism of the ADRB3 gene and overactive bladder. Neurourol Urodyn 2021;40:1780-5. [PMID: 34260097 DOI: 10.1002/nau.24742] [Reference Citation Analysis]
32 Liu B, Ding Y, Li P, Wang T, He S, Jia Z, Yang J. MicroRNA-219c-5p regulates bladder fibrosis by targeting FN1. BMC Urol 2020;20:193. [PMID: 33287818 DOI: 10.1186/s12894-020-00765-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Matsuo T, Miyata Y, Otsubo A, Mukae Y, Mitsunari K, Ohba K, Sakai H. Efficacy of salt reduction for managing overactive bladder symptoms: a prospective study in patients with excessive daily salt intake. Sci Rep 2021;11:4046. [PMID: 33603133 DOI: 10.1038/s41598-021-83725-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Malde S, Marcelissen T, Vrijens D, Apostilidis A, Rahnama'I S, Cardozo L, Lovick T. Sacral nerve stimulation for refractory OAB and idiopathic urinary retention: Can phenotyping improve the outcome for patients: ICI-RS 2019? Neurourol Urodyn 2020;39 Suppl 3:S96-S103. [PMID: 32662561 DOI: 10.1002/nau.24204] [Reference Citation Analysis]
35 Faure Walker N, Gall R, Gall N, Feuer J, Harvey H, Taylor C. The Postural Tachycardia Syndrome (PoTS) Bladder-Urodynamic Findings. Urology 2021;153:107-12. [PMID: 33676954 DOI: 10.1016/j.urology.2021.02.028] [Reference Citation Analysis]
36 Grishin A, Spaska A, Kayumova L. Correction of overactive bladder with botulinum toxin type A (BTX-A). Toxicon 2021;200:96-101. [PMID: 34274378 DOI: 10.1016/j.toxicon.2021.07.005] [Reference Citation Analysis]
37 Scarneciu I, Lupu S, Bratu OG, Teodorescu A, Maxim LS, Brinza A, Laculiceanu AG, Rotaru RM, Lupu AM, Scarneciu CC. Overactive bladder: A review and update. Exp Ther Med 2021;22:1444. [PMID: 34721686 DOI: 10.3892/etm.2021.10879] [Reference Citation Analysis]
38 Fogaing C, Mossa AH, Campeau L. Are Beta 3 Adrenergic Agonists Now the Preferred Pharmacologic Management of Overactive Bladder? Curr Urol Rep 2020;21:49. [PMID: 33090278 DOI: 10.1007/s11934-020-01003-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Wu Y, Qi J, Wu C, Rong W. Emerging roles of the TRPV4 channel in bladder physiology and dysfunction. J Physiol 2021;599:39-47. [PMID: 33052604 DOI: 10.1113/JP279776] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
40 Mostafaei H, Shariat SF, Salehi-Pourmehr H, Janisch F, Mori K, Quhal F, Hajebrahimi S. The clinical pharmacology of the medical treatment for overactive bladder in adults. Expert Rev Clin Pharmacol 2020;13:707-20. [PMID: 32500759 DOI: 10.1080/17512433.2020.1779056] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Sheyn D, Myers S, Tucker D, Hazlett FE Jr, Li X, Conroy B, Hijaz AK. Evaluation of the relationship of cholinergic metabolites in urine and urgency urinary incontinence. Int Urogynecol J 2021. [PMID: 33818647 DOI: 10.1007/s00192-021-04785-z] [Reference Citation Analysis]
42 Firouzmand S, Ajori L, Towse J, Allameh F, Najafi S, Javed S, John B, Langley SEM, Fry CH, Young JS. Investigating the associations of mucosal P2Y6 receptor expression and urinary ATP and ADP concentrations, with symptoms of overactive bladder. Neurourol Urodyn 2020;39:926-34. [PMID: 32049380 DOI: 10.1002/nau.24322] [Reference Citation Analysis]
43 Lim I, Mitsui R, Kameda M, Sellers DJ, Chess-Williams R, Hashitani H. Comparative effects of angiotensin II on the contractility of muscularis mucosae and detrusor in the pig urinary bladder. Neurourol Urodyn 2021;40:102-11. [PMID: 33074588 DOI: 10.1002/nau.24548] [Reference Citation Analysis]
44 Lee WL, Chang CP, Wang PH. Overactive bladder syndrome in nulliparous women. J Chin Med Assoc 2021;84:809-10. [PMID: 34524210 DOI: 10.1097/JCMA.0000000000000579] [Reference Citation Analysis]
45 Karjalainen PK, Tolppanen AM, Mattsson NK, Wihersaari OAE, Jalkanen JT, Nieminen K. Pelvic organ prolapse surgery and overactive bladder symptoms-a population-based cohort (FINPOP). Int Urogynecol J 2021. [PMID: 34245317 DOI: 10.1007/s00192-021-04920-w] [Reference Citation Analysis]
46 Otsubo A, Miyata Y, Matsuo T, Mukae Y, Mitsunari K, Ohba K, Sakai H. Excessive accumulation of visceral fat is associated with lower urinary symptoms including overactive bladder in female patients. Int J Urol 2021;28:397-403. [PMID: 33377223 DOI: 10.1111/iju.14476] [Reference Citation Analysis]
47 Amarenco G, Peyronnet B, Hentzen C. Faut-il remettre en vigueur l’ancienne dichotomie « urgences motrices » – « urgences sensitives » ? Progrès en Urologie 2019;29:1007-10. [DOI: 10.1016/j.purol.2019.04.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Shen YC, Wang HJ, Lee WC, Chen CH, Chuang YC. Intravesical prostatic protrusion does not compromise the therapeutic effects of Mirabegron in male patients with overactive bladder. Int J Clin Pract 2020;74:e13537. [PMID: 32438481 DOI: 10.1111/ijcp.13537] [Reference Citation Analysis]
49 Selvi I, Baydilli N, Arik AI, Basar H. The Effect of Cardiovascular Morbidity on Clinical Responsiveness to Anticholinergics in Postmenopausal Women With Urge Urinary Incontinence. Urology 2021;147:96-103. [PMID: 33159919 DOI: 10.1016/j.urology.2020.10.033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Lo TS, Ng KL, Lin YH, Hsieh WC, Huang TX, Shen YH. De novo detrusor overactivity and urgency after mid-urethral slings for urodynamic stress incontinence. Int Urogynecol J 2021. [PMID: 34292341 DOI: 10.1007/s00192-021-04911-x] [Reference Citation Analysis]
51 Peyronnet B, Chapple C, Cornu JN. Reply to Bernhard Liedl, Klaus Goeschen, and Florian Wagenlehner's Letter to the Editor re: Benoit Peyronnet, Emma Mironska, Christopher Chapple, et al. A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment. Eur Urol 2019, 75:988-1000. Eur Urol 2019;76:e107-8. [PMID: 31326217 DOI: 10.1016/j.eururo.2019.07.004] [Reference Citation Analysis]
52 Kummeling MTM, Egberts J, Elzevier HW, van Koeveringe GA, Putter H, Groenendijk PM. Exploratory analysis of the effect of mirabegron on urodynamic sensation parameters and urethral pressure variations. Int Urogynecol J 2021;32:87-93. [PMID: 32016556 DOI: 10.1007/s00192-019-04193-4] [Reference Citation Analysis]
53 Reekmans M, Janssen JMW, Vrijens DMJ, Smits MAC, van Koeveringe GA, Van Kerrebroeck PEVA. Sacral neuromodulation in patients with refractory overactive bladder symptoms after failed Botulinum toxin therapy: Results in a large cohort of patients. Neurourol Urodyn 2021;40:1120-5. [PMID: 33829519 DOI: 10.1002/nau.24670] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
54 Kummeling MT, Buijs JT, Wisse LJ, van Uhm JI, Elzevier HW, de Ruiter MC, Groenendijk PM. Initial report on distribution of β3-adrenoceptor in the human female urethra. Neurourol Urodyn 2020;39:125-32. [PMID: 31609506 DOI: 10.1002/nau.24183] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
55 Mancini V, Tarcan T, Serati M, Wyndaele M, Carrieri G, Abrams P. Is coexistent overactive-underactive bladder (with or without detrusor overactivity and underactivity) a real clinical syndrome? ICI-RS 2019. Neurourol Urodyn 2020;39 Suppl 3:S50-9. [PMID: 32032454 DOI: 10.1002/nau.24311] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]